vs
Side-by-side financial comparison of STRATASYS LTD. (SSYS) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
STRATASYS LTD. is the larger business by last-quarter revenue ($137.0M vs $103.7M, roughly 1.3× Twist Bioscience Corp). Twist Bioscience Corp runs the higher net margin — -29.4% vs -40.6%, a 11.2% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -2.2%). STRATASYS LTD. produced more free cash flow last quarter ($2.5M vs $-34.8M).
Stratasys, Ltd. is an American-Israeli manufacturer of 3D printers, software, and materials for polymer additive manufacturing as well as 3D-printed parts on-demand. The company is incorporated in Israel. Engineers use Stratasys systems to model complex geometries in a wide range of polymer materials, including: ABS, polyphenylsulfone (PPSF), polycarbonate (PC), polyetherimide and Nylon 12.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
SSYS vs TWST — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $137.0M | $103.7M |
| Net Profit | $-55.6M | $-30.5M |
| Gross Margin | 41.0% | 52.0% |
| Operating Margin | -16.6% | -31.7% |
| Net Margin | -40.6% | -29.4% |
| Revenue YoY | -2.2% | 16.9% |
| Net Profit YoY | -109.0% | 3.4% |
| EPS (diluted) | — | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $103.7M | ||
| Q3 25 | $137.0M | — | ||
| Q2 25 | $138.1M | — | ||
| Q1 25 | $136.0M | — | ||
| Q3 24 | $140.0M | — | ||
| Q2 24 | $138.0M | — | ||
| Q1 24 | $144.1M | — | ||
| Q3 23 | $162.1M | — |
| Q4 25 | — | $-30.5M | ||
| Q3 25 | $-55.6M | — | ||
| Q2 25 | $-16.7M | — | ||
| Q1 25 | $-13.1M | — | ||
| Q3 24 | $-26.6M | — | ||
| Q2 24 | $-25.7M | — | ||
| Q1 24 | $-26.0M | — | ||
| Q3 23 | $-47.3M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | 41.0% | — | ||
| Q2 25 | 43.1% | — | ||
| Q1 25 | 44.3% | — | ||
| Q3 24 | 44.8% | — | ||
| Q2 24 | 43.8% | — | ||
| Q1 24 | 44.4% | — | ||
| Q3 23 | 40.5% | — |
| Q4 25 | — | -31.7% | ||
| Q3 25 | -16.6% | — | ||
| Q2 25 | -12.0% | — | ||
| Q1 25 | -9.1% | — | ||
| Q3 24 | -18.2% | — | ||
| Q2 24 | -18.9% | — | ||
| Q1 24 | -17.0% | — | ||
| Q3 23 | -26.4% | — |
| Q4 25 | — | -29.4% | ||
| Q3 25 | -40.6% | — | ||
| Q2 25 | -12.1% | — | ||
| Q1 25 | -9.6% | — | ||
| Q3 24 | -19.0% | — | ||
| Q2 24 | -18.6% | — | ||
| Q1 24 | -18.0% | — | ||
| Q3 23 | -29.2% | — |
| Q4 25 | — | $-0.50 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | $-0.68 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $71.5M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $852.5M | $456.1M |
| Total Assets | $1.1B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | $71.5M | — | ||
| Q2 25 | $71.1M | — | ||
| Q1 25 | $70.1M | — | ||
| Q3 24 | $64.0M | — | ||
| Q2 24 | $70.9M | — | ||
| Q1 24 | $91.1M | — | ||
| Q3 23 | $104.6M | — |
| Q4 25 | — | $456.1M | ||
| Q3 25 | $852.5M | — | ||
| Q2 25 | $902.4M | — | ||
| Q1 25 | $784.8M | — | ||
| Q3 24 | $831.8M | — | ||
| Q2 24 | $850.5M | — | ||
| Q1 24 | $866.1M | — | ||
| Q3 23 | $883.1M | — |
| Q4 25 | — | $638.1M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.0B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — | ||
| Q3 23 | $1.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.9M | $-24.8M |
| Free Cash FlowOCF − Capex | $2.5M | $-34.8M |
| FCF MarginFCF / Revenue | 1.8% | -33.5% |
| Capex IntensityCapex / Revenue | 3.2% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-11.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-24.8M | ||
| Q3 25 | $6.9M | — | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $4.5M | — | ||
| Q3 24 | $-4.5M | — | ||
| Q2 24 | $-2.4M | — | ||
| Q1 24 | $7.3M | — | ||
| Q3 23 | $-12.7M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $-8.4M | — | ||
| Q1 25 | $789.0K | — | ||
| Q3 24 | $-6.3M | — | ||
| Q2 24 | $-4.9M | — | ||
| Q1 24 | $5.0M | — | ||
| Q3 23 | $-15.0M | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | -6.1% | — | ||
| Q1 25 | 0.6% | — | ||
| Q3 24 | -4.5% | — | ||
| Q2 24 | -3.6% | — | ||
| Q1 24 | 3.5% | — | ||
| Q3 23 | -9.3% | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | 3.2% | — | ||
| Q2 25 | 5.3% | — | ||
| Q1 25 | 2.8% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 1.6% | — | ||
| Q3 23 | 1.4% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSYS
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
